Jessica Tarn
Overview
Explore the profile of Jessica Tarn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry J, Tarn J, Casement J, Lendrem D, Thompson K, Mariette X, et al.
RMD Open
. 2024 Nov;
10(4).
PMID: 39581689
Objectives: The Newcastle Sjogren's Stratification Tool (NSST) stratifies Sjogren's disease patients into four subtypes. Understanding the stability of the subtypes is vital if symptom-based stratification is to be more broadly...
2.
Berry J, Tarn J, Lendrem D, Casement J, Ng W
Rheumatol Immunol Res
. 2024 Apr;
5(1):34-41.
PMID: 38571930
In Sjögren's Syndrome (SS), clinical heterogeneity and discordance between disease activity measures and patient experience are key obstacles to effective therapeutic development. Patient reported outcome measures (PROMs) are useful tools...
3.
Berry J, Tarn J, Casement J, Duret P, Scott L, Wood K, et al.
Ann Rheum Dis
. 2023 Sep;
83(1):88-95.
PMID: 37657927
Objectives: Stratification approaches are vital to address clinical heterogeneity in Sjogren's syndrome (SS). We previously described that the Newcastle Sjogren's Stratification Tool (NSST) identified four distinct clinical subtypes of SS....
4.
Tarn J, Evans E, Traianos E, Collins A, Stylianou M, Parikh J, et al.
Neuromodulation
. 2023 Apr;
26(3):681-689.
PMID: 37032583
Objectives: Fatigue is one of the most important symptoms needing improvement in Primary Sjögren's syndrome (PSS). Previous data from our group suggest that noninvasive stimulation of the vagus nerve (nVNS)...
5.
Cooles F, Tarn J, Lendrem D, Naamane N, Lin C, Millar B, et al.
Ann Rheum Dis
. 2022 Jun;
81(9):1214-1223.
PMID: 35680389
Objectives: An interferon (IFN) gene signature (IGS) is present in approximately 50% of early, treatment naive rheumatoid arthritis (eRA) patients where it has been shown to negatively impact initial response...
6.
Tarn J, Lendrem D, Barnes M, Casement J, Ng W
Front Immunol
. 2022 May;
13:864448.
PMID: 35603172
Introduction: Primary Sjögren's Syndrome (PSS) is a chronic disease characterised by symptoms of oral and ocular dryness, pain, fatigue, anxiety and depression. PSS patients can be subclassified by the pattern...
7.
Tarn J, Lendrem D, McMeekin P, Lendrem C, Hargreaves B, Ng W
J Intern Med
. 2022 Jan;
291(6):849-855.
PMID: 35018685
Introduction: Primary Sjögren's syndrome (pSS) is a chronic inflammatory condition, which presents with symptoms of dryness, pain, fatigue and often symptoms of anxiety and depression. Health-related quality of life (HRQoL)...
8.
Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I, et al.
Rheumatol Int
. 2021 Jun;
41(9):1593-1600.
PMID: 34165604
To re-analyse the clinical outcomes and interferon (IFN) activity data from the JOQUER trial, a phase III trial investigating hydroxychloroquine (HCQ) in patients with primary Sjögren's syndrome (pSS), after stratifying...
9.
Stadnik P, Gilbert S, Tarn J, Charlton S, Skelton A, Barter M, et al.
J Physiol
. 2020 Oct;
599(1):143-155.
PMID: 33052608
Key Points: microRNAs (miRs) are small non-coding molecules that regulate post-transcriptional target gene expression. miRs are involved in regulating cellular activities in response to mechanical loading in all physiological systems,...
10.
Posada J, Valadkhan S, Burge D, Davies K, Tarn J, Casement J, et al.
Arthritis Rheumatol
. 2020 Aug;
73(1):143-150.
PMID: 32798283
Objective: To assess the safety and efficacy of RSLV-132, an RNase Fc fusion protein, in a phase II randomized, double-blind, placebo-controlled clinical trial in patients with primary Sjögren's syndrome (SS)....